Cytochroma announces initiation of Phase II clinical trial of CTA018 for chronic kidney disease patients



    MARKHAM, ON, Oct. 23 /CNW/ - Cytochroma today announced that it has
initiated a Phase II clinical trial of CTA018 Injection, the Company's product
candidate for the treatment of secondary hyperparathyroidism (SHPT) in
patients with chronic kidney disease (CKD). The Phase II clinical trial is an
open label, dose escalating pharmacokinetic, pharmacodynamic, efficacy and
safety study of CTA018 Injection in CKD patients with SHPT undergoing
hemodialysis.
    Joel Z. Melnick, M.D., Cytochroma's Vice-President, Clinical Research and
Development, stated, "Secondary hyperparathyroidism is a serious condition
associated with chronic kidney disease and remains difficult to manage. CTA018
has the unique ability to activate vitamin D signaling pathways as well as
inhibit the CYP24 catabolic enzyme. We believe that CTA018 will provide
improved control of serum parathyroid hormone without the adverse impact on
serum levels of calcium and phosphorus caused by existing agents."
    The Phase II study is being conducted in Canada and will enroll
approximately 40 hemodialysis patients in a maximum of five dose groups. Each
dose group will consist of eight subjects treated for four weeks. Efficacy
will be evaluated by the proportion of subjects who achieve at least a 30%
reduction in intact parathyroid hormone (iPTH) from pre-treatment baseline.
The safety endpoints in this study will include adverse events, physical
assessment, clinical laboratory assessment, selected measures of adjusted
serum total calcium (Ca), serum phosphorus (P), albumin, calculated Ca x P
product, and iPTH.
    In a previous Phase I clinical trial, CTA018 Injection was well tolerated
and produced clinically meaningful reductions in blood levels of iPTH after
less than two weeks of administration. No increases in urinary calcium
excretion were seen.

    About CTA018

    CTA018 is the first compound in a new class of active vitamin D analogs
having a novel dual mechanism of action. CTA018 is designed to be a strong
activator of the vitamin D signaling pathway as well as a potent inhibitor of
CYP24, the intracellular enzyme responsible for the inactivation of vitamin D
hormones. Based on its mechanism of action, CTA018 is expected to be safer and
more effective in treating SHPT than currently available therapies. This
compound was specifically designed by Professor Gary H. Posner, Ph.D. and is
protected under patents and patent applications exclusively licensed to
Cytochroma from the Johns Hopkins University. CTA018 is partnered with
Mitsubishi Tanabe Pharma Corporation under a co-development, and co-promotion
arrangement in the U.S., and an exclusive royalty-bearing license in Asia.

    About Chronic Kidney Disease

    According to the National Kidney Foundation, more than eight million
patients in the U.S. suffer from moderate CKD (Stages 3 and 4) to severe CKD
(Stage 5). Stages 3 and 4 are characterized by progressively decreasing kidney
function as measured by glomerular filtration rate. In Stage 5, kidney
function is minimal to altogether absent and patients require regular dialysis
or kidney transplant for survival. An estimated 70-90% of CKD patients have
vitamin D insufficiency, which can lead to SHPT and resultant debilitating
bone diseases. Mounting evidence continues to link vitamin D insufficiency
with progression of CKD and death. CKD is caused most frequently by diabetes
or hypertension, both of which are consequences of a growing obesity epidemic
in countries worldwide.

    About Secondary Hyperparathyroidism

    SHPT is a condition commonly associated with CKD in which the parathyroid
glands secrete excessive amounts of iPTH. This excess iPTH secretion arises as
a result of impaired kidneys that are neither able to produce sufficient
quantities of active vitamin D hormone nor maintain a state of balance
(homeostasis) between calcium and phosphorus in the body. Prolonged elevation
of iPTH causes excessive calcium to be released from bone into the blood,
leading to softening of the bones (osteomalacia), and calcification of
vascular tissues. SHPT affects approximately 90% of severe, and 40-60% of
moderate CKD patients.

    About Cytochroma

    Cytochroma is a clinical stage specialty pharmaceutical company focused
on developing and commercializing proprietary products to treat and prevent
the clinical consequences of Vitamin D insufficiency and SHPT associated with
CKD. The Company's Vitamin D-based therapeutics are designed to safely and
effectively treat patients with Stage 3, 4 or 5 CKD. Cytochroma has three lead
product candidates in development for CKD patients: CTA018 Injection and
CTAP201 Injection are being developed for the treatment of SHPT, while CTAP101
Capsules are being developed for the treatment of Vitamin D insufficiency. In
addition, Cytochroma is developing novel therapies to treat hyperphosphatemia
in these same patients.
    For more information, please visit www.cytochroma.com.





For further information:

For further information: Cytochroma Investors: Gordon Ngan, Executive
Director, Corporate Development, Tel: (905) 479-5306, ext. 333,
gordon.ngan@cytochroma.com; Cytochroma Media: Robert Stanislaro (FD), Tel:
(212) 850-5657, robert.stanislaro@fd.com

Organization Profile

Cytochroma

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890